



# Representative Legal Matters

## Michael Pilo

Prior to joining Baker McKenzie, Michael advised on the following matters:

### Equity Offerings

- BioAge, a biopharma company targeting the biology of human aging, USD 238 million IPO, USD 11 million concurrent private placement and USD 75 million ATM offering
- BitGo, a digital asset custody and infrastructure company, USD 213 million IPO
- Informatica\*, a cloud data management tech company, USD 841 million IPO and USD 408 million follow-on offering
- Moderna\*, an mRNA medicines biotech company, USD 604.3 million IPO and USD 1.34 billion follow-on offering
- LogicBio Therapeutics, a genetic medicine biotech company, USD 70 million IPO, USD 42 million follow-on offering and USD 50 million ATM offering
- bluebird bio\*, a transformative gene therapy biotech company, aggregate of USD 3.1 billion follow-on offerings
- Habit Restaurants, a fast casual company-owned, franchised and licensed restaurant chain, USD 90 million Up-C IPO and USD 155 million secondary follow-on offering
- Surgery Partners, a healthcare services company, USD 270 million IPO
- Sarepta Therapeutics, a biopharma company focused on unique RNA-targeted therapeutics, aggregate of USD 1.5 billion follow-on offerings
- Stoke Therapeutics, an RNA-based medicines biotech company, USD 125 million follow-on offering and USD 150 million ATM offering and exchange offer
- Seres Therapeutics\*, a microbiome therapeutics platform company, aggregate of USD 286 million follow-on offerings and aggregate of USD 50 million ATM offerings
- KalVista Pharmaceuticals, a small molecule protease inhibitors biopharma company, aggregate of USD 274 million follow-on offerings, and USD 5 million concurrent private placement
- Change Healthcare\*, an independent healthcare technology platform company, USD 640 million Up-C IPO
- nCino\*, a tech company providing cloud-based software for financial institutions, USD 250 million IPO
- Kiniksa Pharmaceuticals\*, a biopharma company, USD 153 million IPO and aggregate of USD 217 million follow-on offerings

- Madrigal Pharmaceuticals\*, a biopharma company, aggregate of USD 666 million primary and secondary follow-on offerings
- Proteostasis Therapeutics\*, a biopharma company, USD 50 million IPO, aggregate of USD 179 million follow-on offerings and aggregate of USD 106 million ATM offerings
- Clementia Pharmaceuticals\*, a rare diseases biopharma company, USD 120 million IPO and USD 70 million follow-on offering
- Dimension Therapeutics\*, a gene therapy platform company, USD 72 million IPO
- Relay Therapeutics\*, a small molecule precision medicines company, USD 400 million IPO
- Karyopharm Therapeutics\*, a pharmaceutical company, aggregate of USD 384 million follow-on public offerings
- Quanterix\*, a research and diagnostics life sciences company, USD 64 million IPO, aggregate of USD 145 million follow-on public offerings and USD 50 million ATM offering
- Radius Health\*, a biopharma company, USD 300 million follow-on offering
- TherapeuticsMD\*, a women's healthcare company, aggregate of USD 389 million follow-on public offerings and USD 50 million ATM offering
- Idera Pharmaceuticals\*, a biopharma company, aggregate of USD 100 million follow-on offerings

## **Debt Offerings**

- Karyopharm Therapeutics\*, a pharmaceutical company, USD 150 million convertible senior notes offering
- Surgery Partners, a healthcare services company, aggregate of USD 770 million senior unsecured notes offering
- Radius Health\*, a biopharma company, USD 300 million convertible senior notes offering
- Planet Fitness, a franchisor and operators of fitness centers, USD 1.275 billion securitized financing facility transaction
- KalVista Pharmaceuticals, a small molecule protease inhibitors biopharma company, USD 143 million convertible senior notes offering
- NFP, a middle market risk, benefits, wealth, and retirement plan advisory solutions company, USD 200 million private debt financing

## **M&A Transactions**

- Nextdoor, a social network tech company, deSPAC business combination with Khosla Ventures Acquisition Co. II



- Escient Pharmaceuticals, a drug discovery and development company, USD 750 million acquisition by Incyte
- Surgery Partners, a healthcare services company, USD 760 million acquisition by Bain Capital

#### **SPAC IPOs**

- Altimeter Growth's USD 450 million IPO
- Ares Acquisition's\* USD 870 million IPO
- Ascendant Digital Acquisition's\* USD 360 million IPO
- Carney Technology Acquisition's\* USD 350 million IPO
- Fortress Capital Acquisition's\* USD 350 million IPO
- Jiya Acquisition's\* USD 100 million IPO
- Juniper Industrial Holding's USD 300 million IPO
- Montes Archimedes Acquisition's\* USD 400 million IPO
- Reinvent Technology Partners'\* USD 600 million IPO
- Reinvent Technology Partners 2's\* USD 200 million IPO
- Sustainable Development Acquisition I's USD 275 million IPO
- TCW Special Purpose Acquisition's USD 450 million IPO

\* Representing the Representatives on behalf of the Underwriters/Initial Purchasers/Placements Agents, including for such investment banks as Goldman Sachs, Morgan Stanley, J.P. Morgan, Barclays, BofA Securities, Citigroup, Leerink, TD Cowen, Jefferies, Deutsche Bank, Evercore, UBS, Guggenheim, and Cantor among others.